Christiaan & Company

Springbok Analytics Muscles $5M Series A Springbok's AI-Powered Muscle Analytics Is Advancing Precision Medicine, Elite Sports Performance, and Longevity on a Global Scale Full Article: https://lnkd.in/g3TjuT-9 CHARLOTTESVILLE, Va., Jan. 24, 2025 /PRNewswire/ - Springbok Analytics (www.springbokanalytics.com), a leader in AI-driven muscle analytics, today announced the close of an oversubscribed $5M Series A funding round. The round was led by Transition Equity Partners, with participation from the National Basketball Association (NBA), Cartan Capital, Boston Global Group and other strategic investors. This funding supports Springbok's mission to advance muscle health analysis across human performance, life sciences, and longevity. "The successful completion of our Series A funding is a significant milestone for Springbok Analytics, reflecting our team's singular focus on establishing the standard of care for muscle health and the growing recognition of our technology's potential," said Springbok Analytics CEO and Co-Founder Scott Magargee. Springbok Analytics has developed a first-of-its-kind, FDA-cleared AI technology that delivers automated, precise and comprehensive muscle health assessments from MRI scans. "Our Series A funding will allow us to expand our reach and continue driving innovation," said Silvia Blemker, Co-Founder and Chief Scientific Officer of Springbok Analytics. "Transition Equity Partners is proud to be a strong and early supporter of Springbok Analytics, having led the company's seed round, and now strengthening the partnership in leading this Series A round," said Patrick Eilers, Managing Partner & Founder of TEP. "Springbok Analytics represents exactly the kind of visionary company that Cartan Capital is proud to support," said CiCi Bellis, Founder and Managing Partner of Cartan Capital. Springbok's other strategic investors include: TitletownTech Anthropy Partners, LLC Getty Performance Scienc CAV Angels Alumni Ventures Driving Innovation Across Life Sciences, Sports, and Longevity Springbok's platform is advancing multiple fields. In life sciences, it enhances clinical trials and research aimed at improving therapies for musculoskeletal conditions. For elite sports, it provides athletes and trainers with precise, data-driven insights to optimize performance and recovery. The company is also addressing the growing demand for longevity solutions, equipping individuals with actionable insights to better manage muscle health as they age. Full Court Capital LLC, a boutique investment bank focused on sports and human performance technology, served as financial advisor to Springbok Analytics for the Series A. For more information about Springbok Analytics or to book your own scan, visit www.springbokanalytics.com.

One of the keys to cutting the cost of drugs in the United States is to raise their cost in other countries, Eli Lilly CEO David Ricks said Tuesday in an interview at the Economic Club of Washington, D.C. “We have to raise developed countries, what they pay, and we can lower the U.S.,” Ricks said. “I think that’s a policy argument we’ll hear about soon with the new administration.” Over the last few years, President Joe Biden’s Inflation Reduction Act—and specifically its Medicare price negotiations—have been a point of contention between the industry and the government. There hasn’t been much clarity on how Trump will approach drug costs. He has threatened to roll back parts of the IRA but he could also consider accelerating or expanding the price negotiations, according to S&P Global in a recent report, citing “bi-partisan support for lowering drug spending and his earlier expressed support for Medicare drug pricing negotiation.”

As we reflect on what we're thankful for this season, we want to take a moment to express our deep gratitude to Jess Hawthorne and CSC Leasing for their ongoing partnership and invaluable support of the Bullpen community. Jess has been a true leader in how he consistently empowers businesses to overcome capital barriers and thrive. From early-stage startups to established enterprises, CSC Leasing continues to provide critical, non-dilutive financing solutions that help companies grow without sacrificing equity. "Lease your equipment. Own your growth." It's more than just a motto—it’s a testament to their commitment to helping businesses, large and small, scale sustainably and efficiently. We're grateful to have partners like Jess and CSC Leasing by our side.

Congratulations Tamika Jackson and The Beautiful Way Foundation on a vibrant and successful kickoff at Portal Innovations, LLC Boston. The people and topics were fantastic and I learned so much about creating equity in clinical trials. Thank you to Lynn Fischer and KMAK Capital for your fundamental support and true leadership in helping to launch this.

First task: Curing #diabetes. Solving oxygenation and immune challenges for stem cells brought together @Giner Inc.’s Linda Tempelman, Cornell University’s Minglin Ma and colleagues to form Persista Bio Inc. Check out the potential impact at our newly launched website! 🎈 👉 Link in comments Let us know what you think about the new site! #biotech #diabetesresearch #stemcells

Check out this interview with our CEO, Chris Seibert at BIO International in San Diego.

Very exciting news for the ChromaTan team! Press blast on the $2 Million award from the NIH for the development of the BioRMB platform for AAV purification. https://lnkd.in/gNnFHZvv #bioprocessing #NIH #AAV

Zenas Zips Up $200M | Zenas BioPharma announced the closing of an upsized $200 million Series C preferred stock financing. Press Release: https://lnkd.in/eaB8cg3D The financing round was led by SR One Capital Management along with New Enterprise Associates (NEA), Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and ArrowMark Partners, along with existing investors, Fairmount Funds Management LLC, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and SuperString Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, CFA, FRM, Partner at Delos Capital , joined Zenas’ Board of Directors. About Zenas BioPharma Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies. For more info about Zenas BioPharma, please visit www.zenasbio.com. About SR One SR One is a transatlantic biotechnology venture capital firm that collaborates with entrepreneurs and investment partners to build elite biotechnology companies. SR One has offices in Redwood City, CA, and Philadelphia, PA, in the US and London in the UK. For more information, please visit www.srone.com. About NEA New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of December 31, 2023, and invests in technology and healthcare companies at all stages in a company's lifecycle. For more info, please visit www.nea.com. About Norwest Venture Partners Norwest Venture Partners is a global venture and growth equity investment firm managing more than $15.5 billion in capital. Since its inception, Norwest has invested in more than 700 companies and currently partners with more than 230 companies in its portfolio. The firm invests in early- to late-stage businesses across key sectors with a focus on enterprise, consumer and healthcare. Norwest has offices in Menlo Park and San Francisco, Calif.; Mumbai, India; and Tel Aviv, Israel. For more info, please visit www.nvp.com. About Delos Capital Delos Capital is a life sciences investment firm pursuing breakthrough medicines that meaningfully improve the lives of patients. Our global team is spread across offices in Cambridge, MA and in East Asia. Delos Capital currently manages three funds, with ~US$600 million in total capital under management. For more info, please visit www.deloscapital.com. Joe Farmer, Jennifer Fox, Tanya Fischer, Gan Wei, Caroline Chevalier #biotech #biopharma #oncology #venture #immunology #immunotherapy #science

Great work from Peter Walker at Carta.

Biopharma Market Update | May 6th | 2024 This is a recap of the Stifel Bank update: https://lnkd.in/gfXgxjxN View the report, it’s awesome: https://lnkd.in/gsvR8iRF 🗞️There renewed hope of a late Summer rate cut according to Sam Goldfarb wrote in the The Wall Street Journal last Friday. 🚀The XBI (US biotechnology stocks index) was up 7.8% for the week, the strongest move in ten weeks. 💥Total biotech market value jumped 8.9% last week and is now up 24.1% for the year. 💩Last week saw no IPOs hit the market although a number of VCs are indicating that we should see a resumption of IPOs this Summer. 🤫 The follow-on market remained quiet last week in sympathy with the macro backdrop. A total of $405 million was raised across 20 issues. 💵 The venture private market was brisk last month with $5.1 billion raised. This was the biggest month for venture capital raises in biotech since June 2022. 💸 Last month saw private issuers take down $2.2 billion in debt capital. This was the most active month thus far in 2024. 🥳It’s been a quiet year for large M&A. Last month was the biggest for M&A this year with $11.5 billion of M&A volume. 😘Last week saw Ono Pharma buy Deciphera for $2.4 billion and Novartis buy Mariana for $1 billion upfront (plus $750 million of potential milestones). 🍔🍕🍟🌭🍰 Investors mouths are drooling… The market is dominated by obesity stories and the three large companies with the most topical obesity stories reported earnings. Last week saw Q1 earnings announcements from Lilly, GSK, Pfizer, Amgen, Regeneron and Novo Nordisk. The questions quickly become (1) who can make enough drug to fill such massive market demand; (2) who can get reimbursement studies done; (3) who can globally expand to meet largely unsatisfied demand in other countries and (4) who has the profile to compete on clinical differentiation. The cash flows generated in this period would not be small compared to share prices today and the player who can deliver will be amply rewarded. 🤘Christiaan & Company is a proud sponsor of the Bullpen and fosters industry and investor relations for early-stage life science companies. See you in the #Bullpen: https://lnkd.in/gkDthNqN